FRT
50
2
MDT
66
2
CI
48
5
ALLE
39
-2
PFE
33
5
DHR
58
2
EL
42
3
OI
33
3
IRM
52
2
SLG
55
3
NTRS
64
4
SEE
55
5
MA
71
2
FITB
60
4
SLB
35
3
EFX
68
2
NWL
41
2
MAR
66
4
MCD
36
-2
SRE
54
2
FRT
50
2
MDT
66
2
CI
48
5
ALLE
39
-2
PFE
33
5
DHR
58
2
EL
42
3
OI
33
3
IRM
52
2
SLG
55
3
NTRS
64
4
SEE
55
5
MA
71
2
FITB
60
4
SLB
35
3
EFX
68
2
NWL
41
2
MAR
66
4
MCD
36
-2
SRE
54
2
Financhill
Back

CASI Pharmaceuticals 10K Form

Sell
16

CASI
CASI Pharmaceuticals

Last Price:
$1.84
Seasonality Move:
-12.63%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CASI News And Ratings

See the #1 stock for the next 7 days that we like better than CASI

CASI Financial Statistics

Sales & Book Value

Annual Sales: $28.5M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $-0.52
Price / Book: 15.65

Profitability

EPS (TTM): -2.55000
Net Income (TTM): $-40.5M
Gross Margin: $11.1M
Return on Equity: -630.22%
Return on Assets: -75.69%

CASI Pharmaceuticals Earnings Forecast

Key CASI Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 29 years for CASI is 39.06%.
  • The Selling, General & Administrative Expenses for CASI have been equal to 145.23% of Gross Profit Margin.
  • The Research & Development expenses have been 31.25% of Revenue.
  • The Net Earning history of CASI is -137.57% of Total Revenues.
  • Per Share Earnings over the last 29 years have been positive in 15 years.

CASI Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CASI
CUSIP: 14757U
Website: casipharmaceuticals.com

Debt

Debt-to-Equity Ratio: -2.29
Current Ratio: 0.81
Quick Ratio: 0.6

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CASI Technical Analysis vs Fundamental Analysis

Sell
16
CASI Pharmaceuticals (CASI) is a Sell

Is CASI Pharmaceuticals a Buy or a Sell?